Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 4:23 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 538965 | NSE: CONCORD

Concord Drugs Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹32.85Overvalued by 53.47%vs CMP ₹70.60

P/E (133.0) × ROE (0.9%) × BV (₹34.40) × DY (2.00%)

₹24.94Overvalued by 64.67%vs CMP ₹70.60
MoS: -183.1% (Negative)Confidence: 63/100 (Moderate)Models: All 7: Overvalued
ModelCategoryValueWeightSignal
PE-ROEEarnings₹25.6730%Over (-63.6%)
Graham NumberEarnings₹20.2522%Over (-71.3%)
Net Asset ValueAssets₹34.4210%Over (-51.2%)
EV/EBITDAEnterprise₹37.0112%Over (-47.6%)
Earnings YieldEarnings₹5.3010%Over (-92.5%)
ROCE CapitalReturns₹33.1610%Over (-53%)
Revenue MultipleRevenue₹18.477%Over (-73.8%)
Consensus (7 models)₹24.94100%Overvalued
Key Drivers: EPS CAGR -21.9% drags value — could be higher if earnings stabilize. | P/E of 133 makes PE-ROE unreliable — asset/earnings models are better benchmarks.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: -21.9%

*Investments are subject to market risks

Investment Snapshot

43
Concord Drugs Ltd scores 43/100 (Weak)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health54/100 · Moderate
ROCE 4.7% WeakROE 0.9% WeakD/E 0.50 ModerateInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money50/100 · Moderate
Promoter holding at 54.4% Stable
Earnings Quality40/100 · Moderate
OPM stable around 9% SteadyWorking capital: 134 days Capital intensive
Quarterly Momentum50/100 · Moderate
Revenue (4Q): +11% YoY GrowingOPM: 5.2% (down 7.0% YoY) Margin pressure
Industry Rank10/100 · Weak
P/E 133.0 vs industry 53.8 Premium to peersROCE 4.7% vs industry 16.4% Below peersROE 0.9% vs industry 15.2% Below peers3Y sales CAGR: -14% Shrinking

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Concord Drugs Ltd Investor Signals

Computed from valuation, cash flow, balance sheet, ownership and quarterly trend data already available in this stock page.

Value Trap Score
40/100
Moderate
Derived from: Cheapness + weak quality + weak cash support
Current data: P/E 133.0 vs Ind 53.8 | ROCE 4.7% | ROE 0.9% | CFO/NP N/A
Balance Sheet Stress
0/100
Comfortable
Derived from: Leverage + debt servicing + liquidity + debt trend
Current data: D/E 0.50x | IntCov 0.0x | Current 2.01x | Borrow/Reserve 0.61x
Cash Flow Reliability
14/100
Weak
Derived from: Cash backing of earnings + working capital pressure
Current data: CFO ₹0 Cr | NP ₹0 Cr | CFO/NP N/A
Ownership Accumulation
0
Neutral
Derived from: FII + DII + promoter direction, adjusted by crowding
Current data: FII N/A | DII N/A | Prom 0.00 pp
Business Momentum
+67
Watch closely
Derived from: Latest quarter sales + profit + OPM change
Current data: Q Sales +67.2% | Q NP +15.8% | Q OPM -4.8 pp
Derived FieldValueHow it is derived
Valuation Gap %-64.7%((Fair Value - CMP) / CMP) × 100
Borrowings / Reserves0.61xLatest borrowings divided by latest reserves
CFO / Net ProfitN/ALatest operating cash flow divided by latest net profit
FII ChangeN/ALatest FII% minus previous FII%
DII ChangeN/ALatest DII% minus previous DII%
Promoter Change0.00 ppLatest promoter% minus previous promoter%
Shareholder Count Change-121Latest shareholder count minus previous count
Quarterly Sales Change+67.2%Latest quarter sales vs previous quarter sales
Quarterly Profit Change+15.8%Latest quarter net profit vs previous quarter net profit
Quarterly OPM Change-4.8 ppLatest quarter OPM minus previous quarter OPM

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 4:23 am

Market Cap 70.6 Cr.
Current Price 70.6
Intrinsic Value₹24.94
High / Low 92.5/29.0
Stock P/E133
Book Value 34.4
Dividend Yield0.00 %
ROCE4.73 %
ROE0.88 %
Face Value 10.0
PEG Ratio-6.08

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Concord Drugs Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Concord Drugs Ltd 70.6 Cr. 70.6 92.5/29.0133 34.40.00 %4.73 %0.88 % 10.0
Orchid Pharma Ltd 2,634 Cr. 519 899/471101 2510.00 %8.07 %8.21 % 10.0
Bacil Pharma Ltd 71.9 Cr. 50.1 51.9/26.797.2 18.40.00 %0.97 %0.98 % 10.0
Astrazeneca Pharma India Ltd 19,630 Cr. 7,852 10,691/6,50294.4 3200.41 %33.4 %23.6 % 2.00
Neuland Laboratories Ltd 16,182 Cr. 12,613 19,748/10,06090.3 1,2630.10 %18.7 %14.8 % 10.0
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of Concord Drugs Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 13.5311.548.797.3812.6214.476.3511.8410.777.9613.3810.0716.84
Expenses 12.0810.807.395.8512.0614.285.6211.059.457.0312.449.0615.96
Operating Profit 1.450.741.401.530.560.190.730.791.320.930.941.010.88
OPM % 10.72%6.41%15.93%20.73%4.44%1.31%11.50%6.67%12.26%11.68%7.03%10.03%5.23%
Other Income 0.000.000.000.010.000.000.000.010.000.000.000.000.02
Interest 0.450.420.390.390.430.380.370.390.430.530.420.400.30
Depreciation 0.380.310.380.380.380.390.340.340.370.370.370.340.30
Profit before tax 0.620.010.630.77-0.25-0.580.020.070.520.030.150.270.30
Tax % 25.81%-600.00%23.81%31.17%-4.00%-39.66%50.00%28.57%57.69%33.33%26.67%29.63%26.67%
Net Profit 0.450.070.490.53-0.24-0.350.010.050.220.010.110.190.22
EPS in Rs 0.510.080.530.57-0.24-0.350.010.050.220.010.110.190.22

Last Updated: March 3, 2026, 11:14 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 27, 2026, 2:46 am

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 33.9540.0250.6857.4351.8048.0851.3451.3358.9651.3143.2636.9348.25
Expenses 30.7232.9942.3851.9347.0244.4348.0048.1153.3746.9739.5833.1644.49
Operating Profit 3.237.038.305.504.783.653.343.225.594.343.683.773.76
OPM % 9.51%17.57%16.38%9.58%9.23%7.59%6.51%6.27%9.48%8.46%8.51%10.21%7.79%
Other Income 0.120.370.150.090.140.090.123.860.100.010.010.010.02
Interest 1.782.722.572.361.881.591.541.421.681.621.591.721.65
Depreciation 1.143.632.912.582.401.711.461.371.761.601.541.421.38
Profit before tax 0.431.052.970.650.640.440.464.292.251.130.560.640.75
Tax % 20.93%33.33%40.74%73.85%50.00%9.09%28.26%23.54%28.89%21.24%25.00%54.69%
Net Profit 0.340.701.750.160.320.410.333.281.590.890.420.300.53
EPS in Rs 0.470.972.420.220.410.520.383.751.820.960.420.300.53
Dividend Payout % 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)105.88%150.00%-90.86%100.00%28.12%-19.51%893.94%-51.52%-44.03%-52.81%-28.57%
Change in YoY Net Profit Growth (%)0.00%44.12%-240.86%190.86%-71.88%-47.64%913.45%-945.46%7.50%-8.78%24.24%

Concord Drugs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:-1%
5 Years:-6%
3 Years:-14%
TTM:8%
Compounded Profit Growth
10 Years:-8%
5 Years:-2%
3 Years:-43%
TTM:880%
Stock Price CAGR
10 Years:2%
5 Years:29%
3 Years:26%
1 Year:70%
Return on Equity
10 Years:3%
5 Years:2%
3 Years:2%
Last Year:1%

Last Updated: September 5, 2025, 3:01 pm

Balance Sheet

Last Updated: March 3, 2026, 2:46 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 7.247.247.247.247.867.868.748.748.749.3210.0010.0010.00
Reserves 7.336.077.8211.7511.4615.2914.7418.0219.6222.3823.8224.1124.42
Borrowings 17.3121.2719.9915.4313.629.839.5712.9716.4315.6314.9316.9114.89
Other Liabilities 12.8019.6317.4421.1173.4849.7924.9610.1511.669.317.557.5612.87
Total Liabilities 44.6854.2152.4955.53106.4282.7758.0149.8856.4556.6456.3058.5862.18
Fixed Assets 20.8418.3215.1813.6413.5111.8510.5213.8313.9712.8611.6312.1711.48
CWIP -0.00-0.00-0.00-0.00-0.000.291.00-0.000.550.921.632.002.05
Investments -0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.001.421.621.621.62
Other Assets 23.8435.8937.3141.8992.9170.6346.4936.0541.9341.4441.4242.7947.03
Total Assets 44.6854.2152.4955.53106.4282.7758.0149.8856.4556.6456.3058.5862.18

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 2.281.753.051.706.881.192.481.620.772.241.963.16
Cash from Investing Activity + -2.14-1.100.23-1.04-2.21-0.34-0.84-3.67-2.44-2.27-1.21-2.32
Cash from Financing Activity + -0.17-0.70-3.42-3.94-4.80-0.73-1.792.071.680.05-0.69-0.87
Net Cash Flow -0.03-0.06-0.14-3.28-0.130.12-0.150.020.010.030.06-0.02
Free Cash Flow -0.380.653.280.664.600.851.63-2.05-1.691.380.940.83
CFO/OP 71%33%51%38%152%36%78%65%26%60%59%89%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-14.08-14.24-11.69-9.93-8.84-6.18-6.23-9.75-10.84-11.29-11.25-13.14

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 180.83249.90183.5199.46501.49367.66180.94147.41141.52116.31117.87125.22
Inventory Days 65.2865.8276.3987.31156.96171.81140.84100.83151.64156.25202.72252.62
Days Payable 140.64207.6492.05129.50559.47393.02109.7226.7662.2545.9835.1745.03
Cash Conversion Cycle 105.47108.09167.8557.2798.98146.44212.05221.48230.90226.58285.41332.82
Working Capital Days 55.4868.04113.144.0079.27102.33103.37140.30112.48145.12126.56134.22
ROCE %7.15%11.35%16.06%8.67%7.48%6.16%6.06%5.36%9.30%5.97%4.48%4.73%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 52.13%52.13%52.13%55.41%55.41%55.41%54.39%54.39%54.39%54.39%54.39%54.39%
Public 47.87%47.87%47.87%44.59%44.60%44.60%45.61%45.61%45.61%45.61%45.61%45.61%
No. of Shareholders 3,2043,1983,9574,0324,7344,7555,0735,0735,2525,1894,7184,597

Shareholding Pattern Chart

No. of Shareholders

Concord Drugs Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23
FaceValue 10.0010.0010.00
Basic EPS (Rs.) 0.340.471.06
Diluted EPS (Rs.) 0.340.471.06
Cash EPS (Rs.) 1.772.032.80
Book Value[Excl.RevalReserv]/Share (Rs.) 34.1133.8234.03
Book Value[Incl.RevalReserv]/Share (Rs.) 34.1133.8234.03
Revenue From Operations / Share (Rs.) 45.2444.9255.91
PBDIT / Share (Rs.) 4.154.054.92
PBIT / Share (Rs.) 2.722.503.17
PBT / Share (Rs.) 0.690.621.34
Net Profit / Share (Rs.) 0.330.471.06
NP After MI And SOA / Share (Rs.) 0.330.471.06
PBDIT Margin (%) 9.169.018.79
PBIT Margin (%) 6.005.555.67
PBT Margin (%) 1.521.402.39
Net Profit Margin (%) 0.741.051.89
NP After MI And SOA Margin (%) 0.741.051.89
Return on Networth / Equity (%) 0.981.393.10
Return on Capital Employeed (%) 6.976.668.07
Return On Assets (%) 0.510.801.69
Long Term Debt / Equity (X) 0.030.010.06
Total Debt / Equity (X) 0.500.490.50
Asset Turnover Ratio (%) 0.730.760.00
Current Ratio (X) 1.562.092.01
Quick Ratio (X) 0.591.021.08
Inventory Turnover Ratio (X) 1.882.090.00
Interest Coverage Ratio (X) 2.052.172.68
Interest Coverage Ratio (Post Tax) (X) 1.171.251.58
Enterprise Value (Cr.) 48.0551.5941.61
EV / Net Operating Revenue (X) 1.061.150.79
EV / EBITDA (X) 11.5812.739.08
MarketCap / Net Operating Revenue (X) 0.680.780.49
Price / BV (X) 0.911.040.80
Price / Net Operating Revenue (X) 0.680.780.49
EarningsYield 0.010.010.03

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Concord Drugs Ltd. is a Public Limited Listed company incorporated on 24/04/1995 and has its registered office in the State of Telangana, India. Company's Corporate Identification Number(CIN) is L24230TG1995PLC020093 and registration number is 020093. Currently company belongs to the Industry of Pharmaceuticals. Company's Total Operating Revenue is Rs. 36.93 Cr. and Equity Capital is Rs. 10.00 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsSurvey No.249, R R District Telangana 501511Contact not found
Management
NamePosition Held
Mr. S Nagi ReddyChairman & Managing Director
Mr. S Manoj Kumar ReddyWhole Time Director
Mr. S Koni ReddyWholeTime Director & CFO
Mr. K Ramachandra ReddyIndependent Director
Ms. Sumeela KasuIndependent Director
Mr. S Nagavenkata HareeshIndependent Director

FAQ

What is the intrinsic value of Concord Drugs Ltd and is it undervalued?

As of 06 April 2026, Concord Drugs Ltd's intrinsic value is ₹24.94, which is 64.67% lower than the current market price of ₹70.60, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (0.88 %), book value (₹34.4), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Concord Drugs Ltd?

Concord Drugs Ltd is trading at ₹70.60 as of 06 April 2026, with a FY2026-2027 high of ₹92.5 and low of ₹29.0. The stock is currently in the middle of its 52-week range. Market cap stands at ₹70.6 Cr..

How does Concord Drugs Ltd's P/E ratio compare to its industry?

Concord Drugs Ltd has a P/E ratio of 133, which is above the industry average of 53.84. This significantly elevated P/E suggests the market expects strong future growth, or the stock may be overpriced relative to current earnings.

Is Concord Drugs Ltd financially healthy?

Key indicators for Concord Drugs Ltd: ROCE of 4.73 % is on the lower side compared to the industry average of 16.35%; ROE of 0.88 % is below ideal levels (industry average: 15.16%). Dividend yield is 0.00 %.

Is Concord Drugs Ltd profitable and how is the profit trend?

Concord Drugs Ltd reported a net profit of ₹0 Cr in Mar 2025 on revenue of ₹37 Cr. Compared to ₹2 Cr in Mar 2022, the net profit shows a declining trend.

Does Concord Drugs Ltd pay dividends?

Concord Drugs Ltd has a dividend yield of 0.00 % at the current price of ₹70.60. The company is currently not paying meaningful dividends.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Concord Drugs Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports